The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Medite Cancer are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Medite Cancer Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward indicators, Medite Cancer is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Begin Period Cash Flow
108 K
Total Cashflows From Investing Activities
-134 K
Free Cash Flow
-3.7 M
Medite
Medite Cancer Relative Risk vs. Return Landscape
If you would invest 0.01 in Medite Cancer Diagnostics on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Medite Cancer Diagnostics or generate 0.0% return on investment over 90 days. Medite Cancer Diagnostics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Medite, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Medite Cancer Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Medite Cancer for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Medite Cancer Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Medite Cancer generated a negative expected return over the last 90 days
Medite Cancer has some characteristics of a very speculative penny stock
Medite Cancer has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (6.81 M) with profit before overhead, payroll, taxes, and interest of 162 K.
Medite Cancer Diagnostics currently holds about 90 K in cash with (3.57 M) of positive cash flow from operations.
Medite Cancer Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Medite Pink Sheet often depends not only on the future outlook of the current and potential Medite Cancer's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Medite Cancer's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding
28.9 M
Short Long Term Debt
376 K
Shares Float
17.3 M
Medite Cancer Fundamentals Growth
Medite Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Medite Cancer, and Medite Cancer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medite Pink Sheet performance.
Assessing Medite Cancer's fundamental ratios provides investors with valuable insights into Medite Cancer's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Medite Cancer is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
Things to note about Medite Cancer Diagnostics performance evaluation
Checking the ongoing alerts about Medite Cancer for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Medite Cancer Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Medite Cancer generated a negative expected return over the last 90 days
Medite Cancer has some characteristics of a very speculative penny stock
Medite Cancer has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (6.81 M) with profit before overhead, payroll, taxes, and interest of 162 K.
Medite Cancer Diagnostics currently holds about 90 K in cash with (3.57 M) of positive cash flow from operations.
Evaluating Medite Cancer's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Medite Cancer's pink sheet performance include:
Analyzing Medite Cancer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medite Cancer's stock is overvalued or undervalued compared to its peers.
Examining Medite Cancer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Medite Cancer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medite Cancer's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Medite Cancer's pink sheet. These opinions can provide insight into Medite Cancer's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Medite Cancer's pink sheet performance is not an exact science, and many factors can impact Medite Cancer's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.